Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 6/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.50 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | UBE2N | P61088 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18166682 | 0.85 | LMNA (0.58) | ADORA2BSMN1; SMN2RXFP1LMNAMAPK1 | |
| SCHEMBL20561098 | 0.79 | LMNA (0.80) | ADORA2BSMN1; SMN2RXFP1LMNAMAPK1 | |
| SCHEMBL17750785 | 0.73 | LMNA (0.89) | ADORA2BSMN1; SMN2RXFP1LMNAMAPK1 | |
| SCHEMBL20561815 | 0.72 | ADORA2B (0.71) | ADORA2BSMN1; SMN2RXFP1LMNAMAPK1 | |
| SCHEMBL14754373 | 0.72 | SMN1; SMN2 (0.65) | ADORA2BSMN1; SMN2RXFP1LMNAMAPK1 | |
| SCHEMBL7018070 | 0.72 | LMNA (0.68) | ADORA2BSMN1; SMN2RXFP1LMNAMAPK1 | |
| SCHEMBL11377514 | 0.72 | RXFP1 (0.64) | ADORA2BSMN1; SMN2RXFP1LMNAMAPK1 | |
| SCHEMBL23297547 | 0.71 | NUDT5 (0.58) | SMN1; SMN2LMNAMAPK1HTTPOLB | |
| SCHEMBL16120984 | 0.71 | ADORA2B (0.81) | ADORA2BSMN1; SMN2RXFP1LMNAMAPK1 | |
| SCHEMBL11377142 | 0.71 | ADORA2B (0.59) | ADORA2BSMN1; SMN2RXFP1LMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3663295-A1 | 2,6-DIOXO,-2,3-DIHYDRO-1H-PURINE COMPOUNDS USEFUL FOR TREATING DISORDERS RELATED TO THE ACTIVITY OF THE TRPA1 CHANNEL | ELI LILLY AND CO. (US) | 2020-06-10 | — | — | EP | disclosed |
| EP-3184527-A1 | 2,6-DIOXO,-2,3-DIHYDRO-1H-PURINE COMPOUNDS USEFUL FOR TREATING DISORDERS RELATED TO THE ACTIVITY OF THE TRPA1 CHANNEL | Hydra Biosciences, Inc. (US) | 2017-06-28 | — | — | EP | disclosed |
| EP-2170309-B1 | 2,6-DIOXO,-2,3-DIHYDRO-1H-PURINE COMPOUNDS USEFUL FOR TREATING DISORDERS RELATED TO THE ACTIVITY OF THE TRPA1 CHANNEL | HYDRA BIOSCIENCES INC (US) | 2016-10-26 | — | — | EP | disclosed |
| US-20130165427-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES | HYDRA BIOSCIENCES, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20120108614-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES | HYDRA BIOSCIENCES, INC. | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108614-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES | ELANE, CASP3, MMP8 | ADORA2B 1599/4885SMN1; SMN2 1895/4885RXFP1 3119/4885 |
| US-20130165427-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES | ELANE, CASP3, MMP8 | ADORA2B 1599/4885SMN1; SMN2 1895/4885RXFP1 3119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.